Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated December 31, 2023, was submitted by Nantahala Capital Management, LLC, along with individuals Wilmot B. Harkey and Daniel Mack, collectively referred to as the Reporting Persons. According to the document, each of the Reporting Persons may be deemed to beneficially own 42,100 shares of Avalo Therapeutics, which represents 4.9% of the company's outstanding common stock. The filing also notes that the Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock. The shares are held by funds and accounts under the control of...Show More
Avalo Therapeutics, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated December 31, 2023, was submitted by Nantahala Capital Management, LLC, along with individuals Wilmot B. Harkey and Daniel Mack, collectively referred to as the Reporting Persons. According to the document, each of the Reporting Persons may be deemed to beneficially own 42,100 shares of Avalo Therapeutics, which represents 4.9% of the company's outstanding common stock. The filing also notes that the Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock. The shares are held by funds and accounts under the control of Nantahala Capital Management, with Harkey and Mack having shared voting and dispositive power over these shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Nantahala Capital Management identified as an investment adviser and Harkey and Mack as control persons. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc.是最近向美国证券交易委员会提交的附表13G/A文件的主体，这表明某些重要投资者的所有权发生了变化。该文件日期为2023年12月31日，由南塔哈拉资本管理有限责任公司以及个人威尔莫特·哈基和丹尼尔·麦克提交，统称为申报人。根据该文件，每位申报人均可被视为实益拥有Avalo Therapeutics的42,100股股票，占该公司已发行普通股的4.9％。该文件还指出，申报人已不再是超过5％的普通股的受益所有人。这些股票由南塔哈拉资本管理公司控制的基金和账户持有，哈基和麦克对这些股票拥有共同的投票权和处置权。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，南塔哈拉资本管理公司被确定为投资顾问，哈基和麦克被确定为控制人。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响Avalo Therapeutics的控制权。
Avalo Therapeutics, Inc.是最近向美国证券交易委员会提交的附表13G/A文件的主体，这表明某些重要投资者的所有权发生了变化。该文件日期为2023年12月31日，由南塔哈拉资本管理有限责任公司以及个人威尔莫特·哈基和丹尼尔·麦克提交，统称为申报人。根据该文件，每位申报人均可被视为实益拥有Avalo Therapeutics的42,100股股票，占该公司已发行普通股的4.9％。该文件还指出，申报人已不再是超过5％的普通股的受益所有人。这些股票由南塔哈拉资本管理公司控制的基金和账户持有，哈基和麦克对这些股票拥有共同的投票权和处置权。该文件是根据1934年《证券交易法》第13d-1（b）条提交的，南塔哈拉资本管理公司被确定为投资顾问，哈基和麦克被确定为控制人。该文件称，这些股份是在正常业务过程中收购的，不是为了改变或影响Avalo Therapeutics的控制权。
有用
没用